©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 10-14, 2026 ISSN: 2579-0781

https://doi.org/10.59298/IDOSR/JES/06/1221014 IDOSRJES12206

Early Infant Diagnosis of HIV: Molecular Screening Strategies and Global Prevention Outcomes

Wotsomu Evasi

Clinical Pharmacology and Antimicrobial resistance Kampala International University Uganda
Email: evasi.wotsomu@stdwc.kiu.ac.ug

ABSTRACT

Pediatric human immunodeficiency virus infection remained a major global health challenge, particularly in regions with high maternal prevalence and limited diagnostic infrastructure. Early infant diagnosis was essential because untreated infants experience rapid disease progression and high mortality within the first two years of life. The purpose of this review was to critically examine the molecular basis, diagnostic technologies, implementation strategies, and global prevention outcomes associated with early infant HIV screening. This narrative review was developed through comprehensive synthesis of current molecular, clinical, and public health literature on nucleic acid-based infant HIV testing and prevention of mother-to-child transmission programs. Evidence demonstrated that virological assays, including HIV DNA and RNA polymerase chain reaction platforms, enabled accurate detection despite persistence of maternal antibodies that confound serological testing. Expansion of point-of-care molecular diagnostics and dried blood spot technologies improved accessibility in resource-constrained settings, contributing to earlier treatment initiation and significant reductions in infant morbidity and mortality. Nevertheless, disparities in infrastructure, turnaround time, and programmatic integration continued to limit universal coverage. Strengthening laboratory capacity, decentralizing testing, and integrating digital health systems are critical to achieving elimination targets.

Keywords: Early infant diagnosis, HIV molecular testing, Polymerase chain reaction, Mother-to-child transmission, Global health outcomes.

INTRODUCTION

Human immunodeficiency virus infection in infants remains a preventable yet persistent contributor to global child morbidity and mortality [1, 2]. Despite substantial progress in prevention of mother-to-child transmission programs, thousands of infants continue to acquire HIV annually, predominantly in sub-Saharan Africa. In the absence of early therapeutic intervention, disease progression in infants is rapid due to immunological immaturity, high viral replication rates, and limited cytotoxic T lymphocyte responses [3]. Mortality rates among untreated infected infants may exceed fifty percent within the first two years of life.

Early infant diagnosis represents a cornerstone of pediatric HIV control strategies. However, conventional serological assays are unreliable in neonates because maternally derived immunoglobulin G antibodies cross the placenta and may persist for up to eighteen months, obscuring the infant's true infection status [4]. This diagnostic limitation necessitates the use of molecular methods capable of detecting viral nucleic acids rather than host antibody responses.

Advances in nucleic acid amplification technologies have enabled accurate detection of HIV DNA and RNA during the early weeks of life [5]. These molecular approaches have transformed pediatric HIV screening and facilitated timely initiation of antiretroviral therapy, which markedly improves survival and neurodevelopmental outcomes. Nonetheless, implementation challenges related to laboratory infrastructure, sample transport, quality assurance, and equitable access remain substantial barriers in high-burden regions. This review examines the virological and immunological basis of early infant diagnosis, evaluates current molecular screening platforms, explores

implementation strategies in resource-limited settings, assesses the impact of early diagnosis on treatment outcomes, and analyzes global prevention frameworks aimed at eliminating vertical transmission. The purpose is to integrate molecular biochemistry with clinical and public health evidence to inform optimized strategies for pediatric HIV prevention.

Virological and Immunological Basis of Early Infant HIV Diagnosis

Mother-to-child transmission of HIV may occur in utero, during labor and delivery, or through breastfeeding [6]. Transmission risk correlates strongly with maternal viral load, placental inflammation, and breastfeeding duration in untreated mothers. Infected neonates exhibit high plasma viral RNA levels within days of acquisition, reflecting unchecked viral replication in the absence of mature immune responses.

The neonatal immune system is characterized by reduced antigen-presenting cell function, diminished interferon responses, and limited cytotoxic T lymphocyte activity [7]. These features permit rapid systemic dissemination of HIV and establishment of viral reservoirs. Consequently, early detection is imperative to prevent irreversible immunological damage.

Serological diagnosis in early infancy is confounded by passive transfer of maternal immunoglobulin G antibodies across the placenta [8]. These antibodies may persist for many months and produce positive antibody-based test results even in uninfected infants. Therefore, detection of viral nucleic acids through polymerase chain reaction assays is required for definitive diagnosis before antibody clearance.

HIV DNA integrated within peripheral blood mononuclear cells can be detected within weeks after infection, while plasma HIV RNA assays identify circulating viral genomes indicative of active replication. The temporal kinetics of viral detectability inform testing schedules, with birth testing identifying in utero infection and subsequent testing at six weeks capturing intrapartum transmission. The biological characteristics of early infant infection thus provide a compelling rationale for nucleic acid-based diagnostic strategies capable of overcoming immunological limitations inherent to neonatal testing.

Molecular Screening Technologies and Diagnostic Platforms

Molecular diagnosis of HIV in infants relies primarily on nucleic acid amplification technologies designed to detect either proviral DNA or viral RNA [9]. HIV DNA polymerase chain reaction assays amplify conserved genomic sequences integrated into host leukocyte DNA. These assays demonstrate high sensitivity and specificity when performed after the first weeks of life.

HIV RNA-based nucleic acid amplification testing quantifies circulating viral RNA and may offer earlier detection in some cases. Real-time quantitative polymerase chain reaction platforms provide rapid amplification and detection with minimal contamination risk, incorporating fluorescent probes to monitor amplification kinetics.

Dried blood spot sampling has significantly enhanced accessibility in remote settings. Capillary blood collected on filter paper is stable at ambient temperatures and can be transported to centralized laboratories without cold chain requirements [10]. This innovation has expanded early infant diagnosis coverage in rural regions.

More recently, point of care molecular platforms have emerged, enabling near patient testing with reduced turnaround time. These systems integrate automated nucleic acid extraction, amplification, and detection within compact devices suitable for decentralized clinics. Rapid result availability facilitates same day clinical decision making and prompt treatment initiation. Analytical performance characteristics of contemporary assays typically exceed ninety five percent sensitivity and specificity when testing occurs at recommended intervals. Nevertheless, quality assurance, proficiency testing, and standardized laboratory protocols remain essential to maintain diagnostic accuracy across diverse settings.

Implementation Strategies in Resource-Limited and High-Burden Settings

Successful implementation of early infant diagnosis requires integration within prevention of mother-to-child transmission programs [11]. Testing algorithms must align with antenatal screening, maternal treatment initiation, and postnatal follow-up systems.

Centralized laboratory models often face challenges related to specimen transport delays and prolonged turnaround times [12]. Delays in result delivery may lead to loss to follow-up and missed opportunities for early therapy. Decentralization of testing through point-of-care platforms mitigates these barriers by enabling on-site diagnosis. Task-shifting strategies, in which trained nurses or laboratory technicians perform molecular assays, have expanded testing capacity in regions with limited specialist personnel. Concurrently, digital reporting systems and electronic medical records enhance tracking of samples and communication of results.

Quality assurance systems are indispensable to ensure reliability. External proficiency testing, internal controls, and standardized operating procedures safeguard analytical integrity. However, infrastructural constraints, reagent stock interruptions, and equipment maintenance challenges continue to impede universal access. Equity considerations are paramount. Geographic disparities, socioeconomic barriers, and gender related factors influence maternal engagement in testing programs [13]. Addressing these determinants requires coordinated health policy, community engagement, and sustained financial investment.

Impact of Early Diagnosis on Treatment Outcomes and Survival

Early identification of HIV infected infants enables prompt initiation of combination antiretroviral therapy, which profoundly alters disease trajectory [14]. Clinical trials have demonstrated that therapy initiated within the first weeks of life significantly reduces mortality compared with deferred treatment. Early treated infants exhibit improved immunological recovery, characterized by preservation of CD4 T lymphocyte counts and suppression of viral replication. Rapid viral suppression limits establishment of long-lived viral reservoirs and may enhance prospects for future remission strategies.

Longitudinal cohort studies confirm that early infant diagnosis programs correlate with decreased hospitalization rates, improved growth parameters, and enhanced neurodevelopmental outcomes [15, 16,17-20]. Cost-effectiveness analyses further demonstrate that early testing and treatment reduce long-term healthcare expenditures by preventing advanced disease complications [17,21-26].

Conversely, delayed diagnosis is associated with severe opportunistic infections, failure to thrive, and irreversible neurocognitive impairment. Thus, molecular screening constitutes not merely a diagnostic intervention but a life-saving therapeutic gateway. The cumulative evidence underscores that early infant diagnosis is central to reducing pediatric HIV mortality and achieving sustainable public health gains.

Global Prevention Outcomes, Policy Frameworks, and Future Directions

Global health initiatives have prioritized elimination of mother-to-child transmission as a critical objective. The World Health Organization recommends virological testing at birth in high-prevalence settings, followed by repeat testing at six weeks and during breastfeeding where applicable [27-33]. Expansion of universal maternal antiretroviral therapy has substantially reduced vertical transmission rates. However, residual transmission persists due to late maternal diagnosis, poor adherence, and acute maternal infection during pregnancy or breastfeeding.

Integration of early infant diagnosis into national health systems has yielded measurable declines in pediatric HIV incidence and mortality [19, 20,34-38]. Digital health innovations, including mobile result reporting and centralized data platforms, improve surveillance and program accountability [21,39-43].

Future directions include development of multiplex molecular assays capable of detecting HIV alongside other neonatal infections, exploration of novel biomarkers for ultra-early detection, and implementation of precision diagnostic algorithms tailored to epidemiological contexts. Sustained political commitment, international funding partnerships, and local capacity building remain essential to achieving global elimination targets and ensuring that molecular innovations translate into equitable health outcomes.

CONCLUSION

Early infant diagnosis of HIV represents a transformative intersection of molecular biochemistry, clinical medicine, and global public health. The unique immunological characteristics of neonates necessitate nucleic acid based diagnostic strategies capable of detecting viral genomes in the presence of persistent maternal antibodies. Advances in polymerase chain reaction technologies, dried blood spot methodologies, and decentralized point of care platforms have expanded access to timely and accurate diagnosis. Implementation within prevention of mother to child transmission programs has demonstrated clear benefits, including earlier treatment initiation, improved immunological recovery, reduced infant mortality, and enhanced long term developmental outcomes. Nevertheless, infrastructural limitations, disparities in access, and operational inefficiencies continue to constrain universal coverage. Bridging laboratory science with effective health system integration is essential to sustain progress toward elimination of pediatric HIV. Continued innovation, quality assurance, and equitable distribution of diagnostic technologies will determine the trajectory of global prevention outcomes. Universal access to high-quality molecular early infant HIV testing integrated within comprehensive maternal and child health systems should be prioritized as a central strategy for eliminating pediatric HIV worldwide.

REFERENCES

1. Evans, C., Jones, C.E., Prendergast, A.J.: HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. The Lancet Infectious Diseases. 16, e92–e107 (2016). https://doi.org/10.1016/S1473-3099(16)00055-4
2. Alum, E., Obeagu, E., P.C., U., Simeon, E., Uti, D., Ukaidi, C., Echegu, A.: Confronting Dual Challenges: Substance Abuse and HIV/AIDS. 2, 1–8 (2024)
3. Vieira, V.A., Herbert, N., Cromhout, G., Adland, E., Goulder, P.: Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era. Front. Immunol. 13, (2022). https://doi.org/10.3389/fimmu.2022.886562
4. Hodinka, R.L.: Serologic Tests in Clinical Virology. In: Lennette's Laboratory Diagnosis of Viral Infections. CRC Press (2010)
5. Gulinaizhaer, A., Zou, M., Ma, S., Yao, Y., Fan, X., Wu, G.: Isothermal nucleic acid amplification technology in HIV detection. Analyst. 148, 1189–1208 (2023). https://doi.org/10.1039/D2AN01813F

6. Prendergast, A.J., Goga, A.E., Waitt, C., Gessain, A., Taylor, G.P., Rollins, N., Abrams, E.J., Lyall, E.H., Perre, P.V. de: Transmission of CMV, HTLV-1, and HIV through breastmilk. The Lancet Child & Adolescent Health. 3, 264–273 (2019). https://doi.org/10.1016/S2352-4642(19)30024-0
7. Sedney, C.J., Harvill, E.T.: The Neonatal Immune System and Respiratory Pathogens. Microorganisms. 11, (2023). https://doi.org/10.3390/microorganisms11061597
8. Pereira, R.A., de Almeida, V.O., Vidori, L., Colvero, M.O., Amantéa, S.L.: Immunoglobulin G and subclasses placental transfer in fetuses and preterm newborns: a systematic review. J Perinatol. 43, 3–9 (2023). https://doi.org/10.1038/s41372-022-01528-w
9. Tsang, H.-F., Chan, L.W.-C., Tong, J.C.-H., Wong, H.-T., Lai, C.K.-C., Au, T.C.-C., Chan, A.K.-C., Ng, L.P.-W., Cho, W.C.-S., Wong, S.-C.C.: Implementation and new insights in molecular diagnostics for HIV infection. Expert Review of Molecular Diagnostics. 18, 433–441 (2018). https://doi.org/10.1080/14737159.2018.1464393
10. Tang, R., Yang, H., Choi, J.R., Gong, Y., You, M., Wen, T., Li, A., Li, X., Xu, B., Zhang, S., Mei, Q., Xu, F.: Capillary blood for point-of-care testing. Critical Reviews in Clinical Laboratory Sciences. 54, 294–308 (2017). https://doi.org/10.1080/10408363.2017.1343796
11. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission, https://www.researchgate.net/publication/378261465_Early_Infant_Diagnosis_Key_to_Breaking_the_Chain_of_HIV_Transmission
12. Simons, C.C., Capraro, G.A.: Centralization versus Decentralization of Clinical Microbiology Laboratory Services: One More Choice To Make During a Global Pandemic. Clinical Microbiology Newsletter. 42, 187–191 (2020). https://doi.org/10.1016/j.clinmicnews.2020.11.001
13. Gupta, M., Angeli, F., Bosma, H., Rana, M., Prinja, S., Kumar, R., Schayck, O.C.P. van: Effectiveness of Multiple-Strategy Community Intervention in Reducing Geographical, Socioeconomic and Gender Based Inequalities in Maternal and Child Health Outcomes in Haryana, India. PLOS ONE. 11, e0150537 (2016). https://doi.org/10.1371/journal.pone.0150537
14. Samson, A.O., Adepoju, A.O., Amusa, M.O.: Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine. 102, e35673 (2023). https://doi.org/10.1097/MD.0000000000035673
15. Valentini, N.C., de Borba, L.S., Panceri, C., Smith, B.A., Procianoy, R.S., Silveira, R.C.: Early Detection of Cognitive, Language, and Motor Delays for Low-Income Preterm Infants: A Brazilian Cohort Longitudinal Study on Infant Neurodevelopment and Maternal Practice. Front. Psychol. 12, (2021). https://doi.org/10.3389/fpsyg.2021.753551
16. Chung, H.W., Chen, J.-C., Chen, H.-L., Ko, F.-Y., Ho, S.-Y., Chang, J.-H., Tsou, K.-I., Tsao, P.-N., Mu, S.-C., Hsu, C.-H., Lien, R., Lin, H.-C., Hsiao, C.-C., Huang, C.-C., Chen, C.-C., on behalf of the Taiwan Premature Infant Follow-up Network: Developing a practical neurodevelopmental prediction model for targeting high-risk very preterm infants during visit after NICU: a retrospective national longitudinal cohort study. BMC Med. 22, 68 (2024). https://doi.org/10.1186/s12916-024-03286-2
17. Madu, C.V., Aloh, H.E., Egba, S.I., Ukaidi, C.U.A., Alum, N.B.: The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa. Medicine (Baltimore). 104, e42300 (2025). https://doi.org/10.1097/MD.0000000000042300
18. World Health Organization: WHO recommendations on the diagnosis of HIV infection in infants and children. World Health Organization, Geneva (2010)
19. Essajee, S., Bhairavabhotla, R., Penazzato, M., Kiragu, K., Jani, I., Carmona, S., Rewari, B., Kiyaga, C., Nkengasong, J., Peter, T.: Scale-up of Early Infant HIV Diagnosis and Improving Access to Pediatric HIV Care in Global Plan Countries: Past and Future Perspectives. JAIDS Journal of Acquired Immune Deficiency Syndromes. 75, S51–S58 (2017). https://doi.org/10.1097/QAI.0000000000001319
20. Diallo, K., Modi, S., Hurlston, M., Beard, R.S., Nkengasong, J.N.: A Proposed Framework for the Implementation of Early Infant Diagnosis Point-of-Care. AIDS Research and Human Retroviruses. 33, 203–210 (2017). https://doi.org/10.1089/aid.2016.0021
21. Ezenwaji, C.O., Alum, E.U., Ugwu, O.P.-C.: Bridging the gap: telemedicine as a solution for HIV care inequities in rural and vulnerable communities. International Journal for Equity in Health. 24, 205 (2025). https://doi.org/10.1186/s12939-025-02584-2
22. Alum EU, Ugwu OPC, Obeagu EI, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. Newport Int J Res Med Sci. 2023;3(2):95–9.
23. Alum EU, Ugwu OPC, Obeagu EI, Okon MB. Curtailing HIV/AIDS spread: impact of religious leaders. Newport Int J Res Med Sci. 2023;3(2):28–31.

24. Obeagu EI, Malot S, Obeagu GU, Ugwu OPC. HIV resistance in patients with sickle cell anaemia. Newport Int J Sci Exp Sci. 2023;3(2).
25. Alum EU, Obeagu EI, Ugwu OPC, Egba SI, Uti DE, Ukaidi CUA. Confronting dual challenges: substance abuse and HIV/AIDS. Elite J HIV. 2024;2(5):1–8.
26. Alum EU, Uti DE, Ugwu OPC, Alum BN. Toward a cure—advancing HIV/AIDS treatment modalities beyond antiretroviral therapy: a review. Medicine. 2024;103(27):e38768.
27. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Alum EU, et al. Hematologic support in HIV patients: blood transfusion strategies and immunological considerations. Newport Int J Biol Appl Sci. 2023;3(3):9–15.
28. Obeagu EI, Obeagu GU, Alum EU, Ugwu OPC. Advancements in immune augmentation strategies for HIV patients. IAA J Biol Sci. 2023;11(1):1–11.
29. Obeagu EI, Obeagu GU, Odo EO, Ugwu OPC, Alum EU. Revolutionizing HIV prevention in Africa: landmark innovations that transformed the fight. IAA J Appl Sci. 2024;11(1):1–12.
30. Obeagu EI, Obeagu GU, Odo EO, Ugwu OPC, Alum EU. Combatting stigma: essential steps in halting HIV spread. IAA J Appl Sci. 2024;11(1):22–9.
31. Obeagu EI, Obeagu GU, Odo EO, Ugwu OPC, Alum EU. Disaster fallout: impact of natural calamities on HIV control. IAA J Appl Sci. 2024;11(1):13–21.
32. Obeagu EI, Ugwu OPC, Alum EU. Nutritional approaches for enhancing immune competence in HIV-positive individuals: a comprehensive review. IDOSR J Appl Sci. 2024;9(1):40–50.
33. Obeagu EI, Obeagu GU, Alum EU, Ugwu OPC. Stigma associated with HIV: a review. Newport Int J Public Health Pharm. 2023.
34. Alum EU, Ugwu OPC, Obeagu EI, Okon MB. Reducing HIV infection rate in women: a catalyst to reducing HIV infection pervasiveness in Africa. Int J Innov Appl Res. 2023;11(10):1–6.
35. Alum EU, Obeagu EI, Ugwu OPC, Aja PM, Ugwu CN, Okon MB. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: a paradigm shift. Medicine. 2023;102(41):e35673.
36. Madu CV, Alum EU, Aloh HE, Ugwu OPC, Obeagu EI, Uti DE, et al. The price of progress: assessing the financial costs of HIV/AIDS management in East Africa. Medicine. 2025;104(18):e42300.
37. Swase DT, Dangana RS, Mbina SA, Mounmbegna PEP, Aja PM, Ugwu OPC, et al. Nanoparticles in HIV treatment for improved drug delivery, clinical translation, and future direction. Discov Nano. 2026;21(6). doi:10.1186/s11671-026-04167-7
38. Swase DT, Ugwu OPC, Chebet J, Mounmbegna PEP, Mbina SA, Aja PM, et al. Molecular, immunological and oncogenic mechanisms of cervical cancer mediated by HPV/HIV co-infection, clinical implication and management. Infect Agents Cancer. 2026. doi:10.1186/s13027-025-00729-0
39. Obeagu EI, Obeagu GU, Alum EU, Ugwu OPC. Comprehensive review of antiretroviral therapy effects on red blood cells in HIV patients. INOSR Exp Sci. 2023;12(3):63–72.
40. Obeagu EI, Obeagu GU, Alum EU, Ugwu OPC. Persistent immune activation and chronic inflammation: unraveling their impact on anemia in HIV infection. INOSR Exp Sci. 2023;12(3):73–84.
41. Obeagu EI, Obeagu GU, Alum EU, Ugwu OPC. Anemia as a prognostic marker for disease progression in HIV infection. IAA J Biol Sci. 2023;11(1):33–44.
42. Obeagu EI, Obeagu GU, Alum EU, Ugwu OPC. Understanding the impact of HIV-associated bone marrow alterations on erythropoiesis. INOSR Sci Res. 2023;10(1):1–11.
43. Obeagu EI, Nwosu DC, Alum EU, Ugwu OPC. Adverse drug reactions in HIV/AIDS patients on highly active antiretroviral therapy: a review of prevalence. Newport Int J Sci Exp Sci. 2023.

CITE AS: Wotsomu Evasi (2026). Early Infant Diagnosis of HIV: Molecular Screening Strategies and Global Prevention Outcomes. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 10-14. https://doi.org/10.59298/IDOSR/JES/06/1221014